Edward B. Pitoniak

Antibodies are a $250B+ market powering therapies, diagnostics, and research — but the discovery process is broken. It’s slow (6–18 months), expensive (millions per candidate), and still relies heavily on animal models. Vici.bio is replacing lab-based antibody discovery with computation. We’ve built an end-to-end AI algorithm that designs antibodies digitally — cutting discovery time from months to hours and reducing cost by 99%. No cages. Just code.